Inventor · disambiguated record

Martin E. Sanders

Also filed as: SANDERS MARTIN · SANDERS MARTIN E

59 granted patents·22 pending applications·371 citations·filing 1985–2025

99Inventor score

Technology areasA61K A61P C07K C07C G01N

Files withIO THERAPEUTICS INC66 SANDERS MARTIN E3 CELTRIX PHARMA2 GENENTECH INC2 US HEALTH2

Top patents by PatentIndex Score

81 records

0199US10980759B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2020·Granted Apr 20, 2021·7 cites·30 claims
0299US9907768B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2017·Granted Mar 6, 2018·25 cites·24 claims
0398US10485775B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Nov 26, 2019·11 cites·20 claims
0498US10471030B2Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Nov 12, 2019·14 cites·20 claims
0598US10231944B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Mar 19, 2019·14 cites·20 claims
0698US10213401B2Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Feb 26, 2019·18 cites·17 claims
0798US10004708B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Jun 26, 2018·18 cites·20 claims
0898US10004709B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Jun 26, 2018·18 cites·20 claims
0997US11065219B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Jul 20, 2021·7 cites·30 claims
1097US10973791B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Apr 13, 2021·7 cites·30 claims
1197US10874627B2Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Dec 29, 2020·6 cites·20 claims
1297US10857117B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Dec 8, 2020·7 cites·30 claims
1397US10835507B2Treatment of muscular disorders with combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2016·Granted Nov 17, 2020·12 cites·15 claims
1497US10806713B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Oct 20, 2020·7 cites·28 claims
1597US10532074B2RAR selective agonists in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Jan 14, 2020·9 cites·8 claims
1697US10517843B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Dec 31, 2019·7 cites·17 claims
1797US10123982B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Nov 13, 2018·10 cites·11 claims
1896US10874628B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Dec 29, 2020·4 cites·17 claims
1995US11793835B2Methods of using RARγ agonists for cancer treatmentIO THERAPEUTICS INC·Filed 2022·Granted Oct 24, 2023·1 cites·17 claims
2095US10966950B2Use of an RXR agonist in treating HER2+ cancersIO THERAPEUTICS INC·Filed 2020·Granted Apr 6, 2021·11 cites·17 claims
2195US10881628B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Jan 5, 2021·3 cites·17 claims
2294US10363272B2RAR selective agonists in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Jul 30, 2019·10 cites·30 claims
2393US11919848B2RXR agonist salt form, polymorphs thereof, and uses thereofIO THERAPEUTICS INC·Filed 2023·Granted Mar 5, 2024·1 cites·20 claims
2493US10532073B2RAR selective agonists in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Jan 14, 2020·3 cites·11 claims
2593US9458241B2Antibody induced cell membrane woundingIGM BIOSCIENCES INC·Filed 2013·Granted Oct 4, 2016·21 cites·20 claims
2692US8377435B2Antibody induced cell membrane woundingUNIV LELAND STANFORD JUNIOR·Filed 2005·Granted Feb 19, 2013·22 cites·20 claims
2791US10874694B2RAR selective agonists in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Dec 29, 2020·2 cites·20 claims
2891US10092535B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2016·Granted Oct 9, 2018·4 cites·22 claims
2989US11786555B2RAR selective agonists in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2020·Granted Oct 17, 2023·1 cites·17 claims
3089US11779558B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2020·Granted Oct 10, 2023·1 cites·14 claims
3189US11737996B2Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2020·Granted Aug 29, 2023·1 cites·20 claims
3289US10987330B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2020·Granted Apr 27, 2021·1 cites·28 claims
3389US9877941B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2016·Granted Jan 30, 2018·3 cites·19 claims
3486US2025248962A1Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
3585US12325685B2RXR agonist salt form, polymorphs thereof, and uses thereofIO THERAPEUTICS INC·Filed 2024·Granted Jun 10, 2025·0 cites·9 claims
3684US12115193B2Methods of using RARγ agonists for cancer treatmentIO THERAPEUTICS INC·Filed 2023·Granted Oct 15, 2024·0 cites·6 claims
3784US10485778B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2018·Granted Nov 26, 2019·1 cites·28 claims
3883US11648223B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2022·Granted May 16, 2023·0 cites·17 claims
3983US2025026714A1METHODS OF USING RARy AGONISTS FOR CANCER TREATMENTIO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
4082US10842764B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Nov 24, 2020·0 cites·30 claims
4182US10702489B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Jul 7, 2020·0 cites·30 claims
4282US10695312B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Jun 30, 2020·0 cites·30 claims
4381US10588881B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Mar 17, 2020·0 cites·30 claims
4481US2021315850A1Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
4581US2023293506A1Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormonesIO THERAPEUTICS·Filed 2023·Application pending·0 cites
4680US12383521B2Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonistsIO THERAPEUTICS INC·Filed 2022·Granted Aug 12, 2025·0 cites·21 claims
4779US11690832B2Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2022·Granted Jul 4, 2023·0 cites·20 claims
4878US6015786AMethod for increasing sex steroid levels using IGF or IGF/IGFBP-3CELTRIX PHARMA·Filed 1997·Granted Jan 18, 2000·33 cites·6 claims
4978US2021275478A1Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
5077US2020345675A1Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2020·Application pending·0 cites

Showing the top 50 of 81 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Martin E. Sanders files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →